Among the nine included studies9, 10, 11, 12, 13, 14, 15, 16, 17 that examined the impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on the risk of mortality in patients with COVID‐19 and diabetes, all of them were retrospective in nature. The gene discussed is GLP1R; the disease is COVID-19.